Botulinum neurotoxins: New questions arising from structural biology

Trends in Biochemical Sciences

Volumn 39, Issue 11, 2014, Pages 517-526

  Kammerer, Richard A ^a   Benoit, Roger M ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Botulinum neurotoxin; Cell surface receptors; Progenitor toxin complex; Subtype; X ray crystallography

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CADHERIN; CADHERIN 1; CARBOHYDRATE; CELL SURFACE RECEPTOR; GANGLIOSIDE; HEMAGGLUTININ; SYNAPTIC VESICLE GLYCOPROTEIN 2; SYNAPTOTAGMIN II; UNCLASSIFIED DRUG; BOTULINUM TOXINS, TYPE A; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PROTEIN BINDING; SV2C PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; BETA SHEET; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; GLYCOSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROCESSING; RECEPTOR BINDING; REVIEW; SURFACE CHARGE; SYNAPSE VESICLE; AMINO ACID SEQUENCE; CHEMISTRY; GENETICS; HUMANS; METABOLISM; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID;

VERTEBRATA;

AMINO ACID SEQUENCE; BOTULINUM TOXINS, TYPE A; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84923190210     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.08.009     Document Type: Review

References (81)

1. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 2010, 79:591-617.
2. Rossetto O., et al. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat. Rev. Microbiol. 2014, 12:535-549.
3. Swaminathan S. Molecular structures and functional relationships in clostridial neurotoxins. FEBS J. 2011, 278:4467-4485.
4. Hill K.K., Smith T.J. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr. Top. Microbiol. Immunol. 2013, 364:1-20.
5. Peck M.W. Biology and genomic analysis of Clostridium botulinum. Adv. Microb. Physiol. 2009, 55:183-265. 320.
6. Whitemarsh R.C., et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect. Immun. 2013, 81:3894-3902.
7. Whitemarsh R.C., et al. Persistence of botulinum neurotoxin A subtypes 1-5 in primary rat spinal cord cells. PLoS ONE 2014, 9:e90252.
8. Dressler D. Clinical applications of botulinum toxin. Curr. Opin. Microbiol. 2012, 15:325-336.
9. Evidente V.G., Adler C.H. An update on the neurologic applications of botulinum toxins. Curr. Neurol. Neurosci. Rep. 2010, 10:338-344.
10. Johnson E.A., Montecucco C. Botulism. Handb. Clin. Neurol. 2008, 91:333-368.
11. Karalewitz A.P., Barbieri J.T. Vaccines against botulism. Curr. Opin. Microbiol. 2012, 15:317-324.
12. Colasante C., et al. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol. Neurobiol. 2013, 48:120-127.
13. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes?. Trends Biochem. Sci. 1986, 11:314-317.
14. Lacy D.B., et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5:898-902.
15. Fotinou C., et al. The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J. Biol. Chem. 2001, 276:32274-32281.
16. Grochulski P., et al. Bacillus thuringiensis CryIA(a) insecticidal toxin: crystal structure and channel formation. J. Mol. Biol. 1995, 254:447-464.
17. Li J.D., et al. Crystal structure of insecticidal delta-endotoxin from Bacillus thuringiensis at 2.5Å resolution. Nature 1991, 353:815-821.
18. Tahirov T.H., et al. Crystal structure of abrin-A at 2.14Å. J. Mol. Biol. 1995, 250:354-367.
19. Swaminathan S., Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7:693-699.
20. Kumaran D., et al. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 2009, 386:233-245.
21. Wang J., et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J. Biol. Chem. 2008, 283:16993-17002.
22. Stenmark P., et al. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 2008, 4:e1000129.
23. Berntsson R.P., et al. Structure of dual receptor binding to botulinum neurotoxin B. Nat. Commun. 2013, 4:2058.
24. Benson M.A., et al. Unique ganglioside recognition strategies for clostridial neurotoxins. J. Biol. Chem. 2011, 286:34015-34022.
25. Brunger A.T., Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009, 54:550-560.
26. Fu Z., et al. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 2009, 48:5631-5641.
27. Rummel A., et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 2009, 110:1942-1954.
28. Rummel A., et al. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 2004, 51:631-643.
29. Schmitt J., et al. Structural analysis of botulinum neurotoxin type G receptor binding. Biochemistry 2010, 49:5200-5205.
30. Stenmark P., et al. Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding. J. Mol. Biol. 2010, 397:1287-1297.
31. Karalewitz A.P., et al. Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 2010, 49:8117-8126.
32. Karalewitz A.P., et al. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry. J. Biol. Chem. 2012, 287:40806-40816.
33. Kroken A.R., et al. Unique ganglioside binding by botulinum neurotoxins C and D-SA. FEBS J. 2011, 278:4486-4496.
34. Kroken A.R., et al. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J. Biol. Chem. 2011, 286:26828-26837.
35. Strotmeier J., et al. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem. J. 2010, 431:207-216.
36. Strotmeier J., et al. The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol. Microbiol. 2011, 81:143-156.
37. Chai Q., et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006, 444:1096-1100.
38. Jin R., et al. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006, 444:1092-1095.
39. Moriishi K., et al. Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochim. Biophys. Acta 1996, 1307:123-126.
40. Peng L., et al. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J. Cell Sci. 2012, 125:3233-3242.
41. Berntsson R.P., et al. Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II. Structure 2013, 21:1602-1611.
42. Benoit R.M., et al. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature 2014, 505:108-111.
43. Dong M., et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
44. Mahrhold S., et al. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580:2011-2014.
45. Vetting M.W., et al. Pentapeptide repeat proteins. Biochemistry 2006, 45:1-10.
46. Nelson R., et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005, 435:773-778.
47. Strotmeier J., et al. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014, 588:1087-1093.
48. Gu S., Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr. Top. Microbiol. Immunol. 2013, 364:21-44.
49. Amatsu S., et al. Crystal structure of Clostridium botulinum whole hemagglutinin reveals a huge triskelion-shaped molecular complex. J. Biol. Chem. 2013, 288:35617-35625.
50. Arndt J.W., et al. The structure of the neurotoxin-associated protein HA33/A from Clostridium botulinum suggests a reoccurring beta-trefoil fold in the progenitor toxin complex. J. Mol. Biol. 2005, 346:1083-1093.
51. Hasegawa K., et al. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J. Biol. Chem. 2007, 282:24777-24783.
52. Inoue K., et al. Structural analysis by X-ray crystallography and calorimetry of a haemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum. Microbiology 2003, 149:3361-3370.
53. Lee K., et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 2013, 9:e1003690.
54. Lee K., et al. High-resolution crystal structure of HA33 of botulinum neurotoxin type B progenitor toxin complex. Biochem. Biophys. Res. Commun. 2014, 446:568-573.
55. Nakamura T., et al. Crystal structure of the HA3 subcomponent of Clostridium botulinum type C progenitor toxin. J. Mol. Biol. 2009, 385:1193-1206.
56. Nakamura T., et al. Molecular diversity of the two sugar-binding sites of the beta-trefoil lectin HA33/C (HA1) from Clostridium botulinum type C neurotoxin. Arch. Biochem. Biophys. 2011, 512:69-77.
57. Yamashita S., et al. Carbohydrate recognition mechanism of HA70 from Clostridium botulinum deduced from X-ray structures in complexes with sialylated oligosaccharides. FEBS Lett. 2012, 586:2404-2410.
58. Lee K., et al. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science 2014, 344:1405-1410.
59. Gu S., et al. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 2012, 335:977-981.
60. Burkard F., et al. Electron density projection map of the botulinum neurotoxin 900-kilodalton complex by electron crystallography. J. Struct. Biol. 1997, 120:78-84.
61. Benefield D.A., et al. Molecular assembly of botulinum neurotoxin progenitor complexes. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:5630-5635.
62. Pier C.L., et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011, 585:199-206.
63. Fischer A., et al. Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog. 2008, 4:e1000245.
64. Fischer A., et al. Beltless translocation domain of botulinum neurotoxin A embodies a minimum ion-conductive channel. J. Biol. Chem. 2012, 287:1657-1661.
65. Dong M., et al. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 2008, 19:5226-5237.
66. Montecucco C., et al. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 2004, 12:442-446.
67. Jacky B.P., et al. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog. 2013, 9:e1003369.
68. Muraro L., et al. The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem. Biophys. Res. Commun. 2009, 380:76-80.
69. Arnon S.S., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
70. Schivell A.E., et al. SV2A and SV2C contain a unique synaptotagmin-binding site. Mol. Cell. Neurosci. 2005, 29:56-64.
71. Sciarretta K.L., et al. Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 2006, 413:273-312.
72. Markey A.C. Botulinum A exotoxin in cosmetic dermatology. Clin. Exp. Dermatol. 2000, 25:173-175.
73. Mahrhold S., et al. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem. J. 2013, 453:37-47.
74. Ahnert-Hilger G., et al. Synaptic vesicle proteins: targets and routes for botulinum neurotoxins. Curr. Top. Microbiol. Immunol. 2013, 364:159-177.
75. Lynch B.A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9861-9866.
76. Dong M., et al. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell Biol. 2007, 179:1511-1522.
77. Nishiki T., et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 1994, 269:10498-10503.
78. Rummel A., et al. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 2004, 279:30865-30870.
79. Sudhof T.C. Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 2013, 80:675-690.
80. Peng L., et al. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 2011, 7:e1002008.
81. Nakamura T., et al. Sugar-binding sites of the HA1 subcomponent of Clostridium botulinum type C progenitor toxin. J. Mol. Biol. 2008, 376:854-867.